Viewing nowCombinationDapa M Sustained Release Tablets 5/1000 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aprogen Bioscience, Co., Ltd.

MFDS item code 202106875 · Approved 2021.10.12 · Insurance code 645210660
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in combination with dapagliflozin and metformin, along with dietary and exercise therapy, to assist in controlling blood sugar levels in adult patients with type 2 diabetes. Particularly for patients whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors, refer to professional information regarding the impact of this medication on the occurrence of cardiovascular events. It is effectively used to improve blood sugar control.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same metformin dose the patient was taking, or the closest appropriate therapeutic dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously taking. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering agents. Since such a change may cause changes in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted by the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients, Patient subsection).
This medication is used to treat diabetes and helps to control blood sugar levels. It may rarely cause a serious condition known as lactic acidosis, so caution should be exercised especially in patients with poor kidney function, heart disease, infections, etc. When used with other diabetes medications, hypoglycemic symptoms may occur, necessitating dose adjustments and symptom monitoring. This medication should not be used in patients with moderate to severe renal impairment, dehydration, severe infections, acute myocardial infarction, etc. If undergoing a radiographic examination with contrast agents, this medication should be discontinued for at least 48 hours prior to the examination and should only be resumed once kidney function is confirmed to be normal after the examination. If surgery is planned, this medication should also be temporarily discontinued 48 hours before surgery and resumed only after confirming that kidney function is normal after surgery. Women who are pregnant or may become pregnant, as well as nursing mothers, should not use this medication. Elderly patients or those with weak kidney function require dosage adjustments and monitoring of kidney function, and should be cautious if there is a high risk of hypotension or dehydration. During the use of this medication, genital infections or urinary tract infections may occur, and if symptoms of infection appear, immediate consultation with a physician is necessary. Vitamin B12 deficiency may occur, so it is advisable to check vitamin B12 levels during prolonged use. Excessive alcohol intake can increase the risk of side effects from this medication, so it should be avoided. Caution is required when driving or operating machinery as dizziness may occur. This medication should be stored out of the reach of children and kept in its original container for safety. If any unusual symptoms or discomfort occur while taking this medication, healthcare personnel should be notified immediately.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a well-closed container. It is best stored at room temperature, between 1 to 30 degrees Celsius, away from extreme heat or cold.
Dark pink, double convex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aprogen Bioscience, Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.